VQD-002 Triciribine AKT Inhibitors
| Product name:VQD-002 Triciribine | Purity:98% min |
| CAS NO:35943-35-2 | Solubility:DMSO : 100 mg/mL (312.21 mM) |
| Molecular Formula:C13H16N6O4 | Package:Package according to customer requirements |
| Molecular Weight:320.304 | Storage:Store at -20℃ |
Triciribine, also known as VQD-002, is a potent AKT inhibitor and a cell-permeable tricyclic nucleoside molecule with potential antineoplastic activity. Triciribine inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3, which may result in the inhibition of Akt-expressing tumor cell proliferation. Akts are anti-apoptotic serine/theronine-specific protein kinases that phosphorylate and inactivate components of the apoptotic machinery, including Bcl-xL/Bcl-2-associated death promoter (BAD) and caspase 9.
Related Products:
MK-2206 2HCl; Ipatasertib; PHT-427; Capivasertib; Perifosine; CCT128930; AT7867; AT13148; ONC-201; Akti-1/2; SC66; Miltefosine; GSK690693
[1]. Dieterle A, et al. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer. 2009 Aug 15;125(4):932-41.
[2]. Gürsel DB, et al. Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies. Neuro Oncol. 2011 Jun;13(6):610-21.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.